External Evaluation of a Plasma and Cerebrospinal Fluid Population Pharmacokinetics Model of Meropenem in Infants.

Key Points

• To evaluate the pharmacokinetics of meropenem in infants using a model that includes plasma and cerebrospinal fluid concentrations.
• External evaluation of the NeoMero model
• Assessment of pharmacokinetics in plasma and cerebrospinal fluid
• Comparison of dosing regimens based on target MIC
• Proposed dosing regimens of 20 or 40 mg/kg every 8 hours are effective
• Dosing adjustments are based on gestational and postnatal age
• The model supports substantial bacterial killing in the CNS